Drug Targeting to the Brain
The DOI matches its Crossref record; 208 of the 208 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Regulated portals of entry into the cell
Conner, S. D., & Schmid, S. L. (2003) · Nature · doi:10.1038/nature01451 · Cited by 3,805
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Ghose, A. K., Viswanadhan, V. N., & Wendoloski, J. J. (1999) · Journal of Combinatorial Chemistry · doi:10.1021/cc9800071 · Cited by 3,068
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
FINE STRUCTURAL LOCALIZATION OF A BLOOD-BRAIN BARRIER TO EXOGENOUS PEROXIDASE
Reese, T. S., & Karnovsky, M. J. (1967) · The Journal of Cell Biology · doi:10.1083/jcb.34.1.207 · Cited by 2,629
JUNCTIONS BETWEEN INTIMATELY APPOSED CELL MEMBRANES IN THE VERTEBRATE BRAIN
Brightman, M. W., & Reese, T. S. (1969) · The Journal of Cell Biology · doi:10.1083/jcb.40.3.648 · Cited by 2,471
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R., & Bertino, J. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.2.695 · Cited by 1,750
Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection
Oldendorf, W. (1971) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1971.221.6.1629 · Cited by 1,683
Cited by
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
“However, in recent years, only a minor number of brain-directed pharmaceuticals have reached the market (3–5%) since most of them were incapable of crossing the BBB in vivo [38].”
BackgroundApproaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases
Gabathuler, R. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.028 · Cited by 802
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
The blood-brain barrier: an engineering perspective
Wong, A. D., Ye, M., Levy, A. F., Rothstein, J. D., Bergles, D. E., & Searson, P. C. (2013) · Frontiers in Neuroengineering · doi:10.3389/fneng.2013.00007 · Cited by 662
“The lipid composition of the membrane of human BMECs is ∼33% phosphatidyl choline (PC), 25% phosphatidyl ethanolamine (PE), 17% sphyngomyelin (Sph), 11% phosphatidyl serine (PS), 4.8% phosphatidyl inositol (PI; Siakotos et al., 1969; Tewes and Galla, 2001).”
BackgroundInfluentialProgress and perspectives on targeting nanoparticles for brain drug delivery
Gao, H. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.05.013 · Cited by 495
Getting into the Brain: Approaches to Enhance Brain Drug Delivery
Patel, M. M., Goyal, B. R., Bhadada, S. V., Bhatt, J. S., & Amin, A. F. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00003 · Cited by 461
Aryal, M., Arvanitis, C. D., Alexander, P. M., & McDannold, N. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.008 · Cited by 443
Biomaterials for promoting brain protection, repair and regeneration
Orive, G., Anitua, E., Pedraz, J. L., & Emerich, D. F. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2685 · Cited by 421
Interactive Association of Drugs Binding to Human Serum Albumin
Yang, F., Zhang, Y., & Liang, H. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15033580 · Cited by 376
“can pass through the blood brain barrier [87–92].”
BackgroundHu, K., Li, J., Shen, Y., Lu, W., Gao, X., Zhang, Q., & Jiang, X. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.10.016 · Cited by 354
Xin, H., Sha, X., Jiang, X., Zhang, W., Chen, L., & Fang, X. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.07.046 · Cited by 311
Challenges in design and characterization of ligand-targeted drug delivery systems
Muro, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.052 · Cited by 307
Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
Tabrizi, M., Bornstein, G. G., & Suria, H. (2010) · The AAPS Journal · doi:10.1208/s12248-009-9157-5 · Cited by 305
PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors
He, H., Li, Y., Jia, X.-R., Du, J., Ying, X., Lu, W.-L., Lou, J.-N., & Wei, Y. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.09.002 · Cited by 303
Repairing the human brain after stroke. II. Restorative therapies
Cramer, S. C. (2008) · Annals of Neurology · doi:10.1002/ana.21412 · Cited by 285
Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles
Gao, H., Qian, J., Cao, S., Yang, Z., Pang, Z., Pan, S., Fan, L., Xi, Z., Jiang, X., & Zhang, Q. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.03.058 · Cited by 280
Choi, J. J., Feshitan, J. A., Baseri, B., Wang, S., Tung, Y.-S., Borden, M. A., & Konofagou, E. E. (2010) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2009.2034533 · Cited by 261
Blood-brain barrier transport machineries and targeted therapy of brain diseases
Barar, J., Rafi, M. A., Pourseif, M. M., & Omidi, Y. (2016) · BioImpacts · doi:10.15171/bi.2016.30 · Cited by 257
Downs, M. E., Buch, A., Sierra, C., Karakatsani, M. E., Chen, S., Konofagou, E. E., & Ferrera, V. P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125911 · Cited by 220
Lipid Nanoparticles: Effect on Bioavailability and Pharmacokinetic Changes
Souto, E. B., & Müller, R. H. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_4 · Cited by 210
Gan, C. W., & Feng, S.-S. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.06.053 · Cited by 207
Noncoding RNAs in Alzheimer's disease
Idda, M. L., Munk, R., Abdelmohsen, K., & Gorospe, M. (2018) · WIREs RNA · doi:10.1002/wrna.1463 · Cited by 207
“Therefore, additional efforts are needed to ensure that therapeutic ncRNAs are delivered intact to the proper cell types and compartments, cross the blood–brain barrier (BBB) if necessary, and arrive in therapeutic concentrations.”
Zhang, M., Zang, X., Wang, M., Li, Z., Qiao, M., Hu, H., & Chen, D. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb00170k · Cited by 205
Brain insulin, energy and glucose homeostasis; genes, environment and metabolic pathologies
Gerozissis, K. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.050 · Cited by 196
“Nonetheless, new therapeutic strategies are under active investigation to improve central delivery of drugs (Pardridge, 2007; Prodi and Obici, 2006; Reger and Craft, 2006; Stockhorst et al., 2004).”
BackgroundMastroberardino, P. G., Hoffman, E. K., Horowitz, M. P., Betarbet, R., Taylor, G., Cheng, D., Na, H. M., Gutekunst, C.-A., Gearing, M., Trojanowski, J. Q., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.02.009 · Cited by 195
Arvanitis, C. D., Livingstone, M. S., Vykhodtseva, N., & McDannold, N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045783 · Cited by 194
“This is particularly important in the brain, where the blood brain barrier (BBB) excludes most molecules from being delivered from the bloodstream and precludes the use of many drugs [1] for central nervous system (CNS) applications.”
BackgroundPhase I Study of GRN1005 in Recurrent Malignant Glioma
Drappatz, J., Brenner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., Mikkelsen, T., Rosenfeld, S., Sarantopoulos, J., Meyers, C. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2481 · Cited by 190
Samiotaki, G., Vlachos, F., Tung, Y., & Konofagou, E. E. (2012) · Magnetic Resonance in Medicine · doi:10.1002/mrm.23063 · Cited by 172
“The BBB acts as a physical and metabolic barrier, with a range of passive and active features, which restricts the penetration of molecules, except if they are both lipid soluble and of a molecular weight (MW) under 400 Da (3).”
Staquicini, F. I., Ozawa, M. G., Moya, C. A., Driessen, W. H. P., Barbu, E. M., Nishimori, H., Soghomonyan, S., Flores, L. G., Liang, X., Paolillo, V., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44798 · Cited by 165
Strategies To Deliver Peptide Drugs to the Brain
Lalatsa, A., Schatzlein, A. G., & Uchegbu, I. F. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400680d · Cited by 160
In vivo, in vitro and in silico methods for small molecule transfer across the BBB
Mensch, J., Oyarzabal, J., Mackie, C., & Augustijns, P. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21745 · Cited by 160
Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria
Haqqani, A. S., Bélanger, K., & Stanimirovic, D. B. (2024) · Frontiers in Drug Delivery · doi:10.3389/fddev.2024.1360302 · Cited by 153
“…brain cell types (Zhang et al., 2016; McKenzie et al., 2018; Hu et al., 2020) including astrocytes, oligodendrocytes, neurons and microglia and in peripheral organs (Li et al., 2002; Pardridge, 2007; Bangsow et al., 2008; Feng et al., 2019; Hu et al., 2020) such as liver, kidney, heart and lung.”
Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line.
Markoutsa, E., Pampalakis, G., Niarakis, A., Romero, I. A., Weksler, B., Couraud, P.-O., & Antimisiaris, S. G. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.11.015 · Cited by 122
Dufès, C., Al Robaian, M., & Somani, S. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.21 · Cited by 110
Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases
Anthony, D. P., Hegde, M., Shetty, S. S., Rafic, T., Mutalik, S., & Rao, B. S. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119326 · Cited by 110
Differential receptor-mediated drug targeting to the diseased brain
Rip, J., Schenk, G., & de Boer, A. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902806383 · Cited by 98
Soliman, H. M., Ghonaim, G. A., Gharib, S. M., Chopra, H., Farag, A. K., Hassanin, M. H., Nagah, A., Emad-Eldin, M., Hashem, N. E., Yahya, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910794 · Cited by 81
“However, further clinical applications of Que were stopped because of their poor solubility, reduced systematic concentration, and inability to penetrate the BBB [70,71].”
BackgroundInfluentialDerakhshankhah, H., Sajadimajd, S., Jafari, S., Izadi, Z., Sarvari, S., Sharifi, M., Falahati, M., Moakedi, F., Muganda, W. C. A., Müller, M., et al. (2020) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2020.102149 · Cited by 48
Genetic approach for intracerebroventricular delivery
Regev, L., Ezrielev, E., Gershon, E., Gil, S., & Chen, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907059107 · Cited by 35
Increased brain uptake of pterostilbene loaded folate modified micellar delivery system
Wang, Y., Su, Y., Yang, Y., Jin, H., Wu, M., Wang, Q., Sun, P., Zhang, J., Yang, X., & Shu, X. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2126559 · Cited by 25
“Inevitably, these approaches have brought great inconvenience and pain to patients (Pardridge, 2007).”
Background
Metadata
- Authors
- Pardridge, W. M.
- Venue
- Pharmaceutical Research
- Published
- 2007-06-07
- Volume
- 24
- Issue
- 9
- Pages
- 1733-1744
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W2055233461
- Cited by
- 447
- References
- 208
- FWCI
- 15.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.